In June 2026, the UK and France formalised a landmark science and technology agreement that reshapes collaboration frameworks for researchers, innovators, and early-stage companies on both sides of the Channel. The deal—negotiated over 18 months and signed ahead of broader European science cooperation discussions—removes administrative friction, creates reciprocal funding access, and establishes new pathways for joint research projects that can benefit UK startups in deep tech, climate, biotech, and digital innovation.

For UK founders and startup teams, this matters immediately. Access to French grant schemes, participation in EU-adjacent research programmes, and the ability to form legally recognised cross-border research partnerships now sits within reach—without the post-Brexit complications that have stalled collaboration over the past five years. This article breaks down the policy mechanics, the sectors poised to benefit most, and the practical steps founders should take now.

What the UK-France Science and Technology Agreement Actually Changes

The agreement centres on three core mechanisms: reciprocal research funding access, mutual recognition of research institutions and qualifications, and harmonised IP frameworks for cross-border projects. It does not restore UK membership of Horizon Europe—that door remains firmly closed—but it does create side-channels that bypass some of the friction points that have slowed UK-EU collaboration since 2020.

Previously, UK startups seeking to partner with French research institutes faced a dual burden: identifying eligible partners, then navigating separate funding application systems. A UK deep-tech founder working on quantum computing, for example, would need to apply for UK Research and Innovation (UKRI) grants independently, while their French counterpart applied to Agence Nationale de la Recherche (ANR). Coordination was possible but clunky. Timing misaligned. IP ownership became a grey zone.

Under the new framework:

  • Dual-funding pathways: UK and French research councils now accept joint applications from mixed-nationality teams. UKRI and ANR have agreed to synchronised application windows and shared assessment criteria for projects involving both countries.
  • Portable research credits: Researchers and companies can now move between the UK and France while retaining access to active research grants, provided they maintain active involvement in the original project.
  • Shared IP ownership: The agreement clarifies that inventions developed in joint projects are co-owned by both jurisdictions' parties, with commercial rights decided upfront in project contracts.
  • Fast-track institutional recognition: UK universities and research-active companies (including startups) can now register with French research authorities without lengthy accreditation delays, and vice versa.

The deal also establishes a UK-France Innovation Fund, a £180m pot (matched by French investment) specifically for early-stage companies and scale-ups working on jointly-identified priority sectors: clean energy, AI and quantum computing, life sciences, and advanced manufacturing.

Funding Streams Now Open to UK Startups

Several concrete funding routes have unlocked for UK founders as of Q2 2026:

1. Joint ANR-UKRI Research Grants

The Agence Nationale de la Recherche (ANR) manages approximately €600m annually in competitive research funding. UK startups with French research partners can now co-apply for ANR funding under the "international collaboration" track. Historically, UK teams were excluded post-Brexit; now, provided the project involves genuine UK-France partnership, both parties can access ANR funding.

The application process: form a consortium with a UK organisation (university or registered company) and a French partner (research institute, university, or company). Submit a single joint proposal to UKRI's Innovation and Technology sector team, which forwards eligible applications to ANR. Assessment happens in parallel; both councils fund simultaneously if approved.

Award size: typically £150k–£500k per partner per project, over 3 years. Deadline for next round: November 2026.

2. UK-France Innovation Fund

This new £180m bilateral fund prioritises early-stage companies (typically Seed to Series A) in priority sectors. Unlike traditional research grants, this fund operates more like a co-investment mechanism: UK and French funders match private investment raised by qualifying startups.

Key terms:

  • Eligible companies: UK-registered startups with material R&D operations and at least one French founder, investor, or research partner.
  • Match structure: if your startup raises £500k from institutional investors, the Innovation Fund contributes up to 50% additional (so £250k) as dilutive or non-dilutive capital.
  • Deployment: managed by designated investment bodies in each country. In the UK, Innovate UK Growth is the distribution partner; in France, Bpifrance handles allocation.
  • First applications open: July 2026.

3. Bilateral Researcher Mobility Grants

Both councils now fund researcher exchange programmes. UK-based PhD students and postdocs can spend 3–12 months at French institutions with full funding; French researchers can reciprocate. For startups, this means easier access to specialist talent and embedded research partnerships without full hiring commitments.

Award: €20k–€60k per researcher per year. Open application window, rolling basis.

Which Sectors Benefit Most—And Why

The agreement explicitly prioritises four sectors, but the mechanics favour founders in deep tech and research-heavy verticals:

Clean Energy and Climate Tech

France excels in nuclear, grid infrastructure, and energy storage research; the UK leads in offshore wind, green hydrogen, and carbon capture. Joint projects are already being designed. A UK battery-chemistry startup partnering with France's Institut de Recherche et Développement sur l'Énergie Photovoltaïque (IRDEP) can now access both UKRI funding and ANR grants—unlocking faster R&D cycles and faster path to demonstration.

Expected impact: 15–20 new joint clean-tech projects by end of 2026.

AI and Quantum Computing

The UK has strengths in AI training, data infrastructure, and machine learning applications (Cambridge, Oxford, Imperial). France holds world-class research in quantum architecture and cryptography (Université de Lorraine, Inria). Cross-border teams now access £40m+ jointly allocated to AI-quantum research in 2026–2027.

For startups: if you're building quantum algorithms or AI infrastructure, partnership with a French lab now unlocks non-dilutive research funding, IP clarity, and access to French computational resources (France's Plan Quantique allocated €200m to quantum infrastructure over 5 years).

Life Sciences and Biotech

Both countries have robust biotech ecosystems. The UK (Oxford, Cambridge, Imperial) and France (Institut Pasteur, INSERM) have complementary strengths in cell therapy, genomics, and immunology. The new framework removes visa and research-permit friction that previously slowed lab exchanges and clinical trial setup.

Early-stage biotech founders can now spin out from French universities and maintain UK subsidiary operations—or vice versa—without duplicate compliance audits or funding-stream conflicts.

Advanced Manufacturing and Materials

Aerospace, automotive, and precision manufacturing account for significant R&D investment in both countries. The agreement fast-tracks access to French digital manufacturing networks (e.g., Aerospace Valley in Toulouse) for UK startups, and vice versa.

How to Access These Funds: A Practical Founder Roadmap

Step 1: Identify a Research or Innovation Partner in France

This is non-negotiable. The agreement requires genuine partnership—not just a name on letterhead. Options:

  • Universities and public labs: Contact department leads at Sorbonne, INSERM, CNRS, or Institut Pasteur. They have international collaboration teams and are incentivised to set up UK partnerships.
  • Government-backed innovation networks: Bpifrance's SME network, or regional clusters (e.g., Toulouse aeronautics, Grenoble IT).
  • Corporate R&D arms: Large French tech or industrial companies (Airbus, Valeo, Sanofi) often partner with startups on specific R&D workstreams.
  • Consultants and brokers: Organisations like British Council France now offer matching services to connect UK founders with French research institutions.

Step 2: Register as a Dual-Jurisdiction Entity (If Pursuing ANR Funding)

If applying for ANR grants, your UK company should establish a registration with the French research authorities. This is simpler under the new agreement but still required. You'll need:

  • UK Companies House certificate of incorporation.
  • Proof of active R&D operations in your field.
  • Designation of a French contact point (can be a partner researcher or hired consultant).
  • SIRET (French business registration number) for your French operations, if applicable.

Processing time: 4–6 weeks. Cost: £0–£500, depending on whether you use a local consultant.

Step 3: Choose Your Funding Stream and Timeline

  • ANR-UKRI joint research grants: Deadline November 2026; 6–9 month assessment; funding start April 2027. Best for deep-tech R&D with clear milestones.
  • UK-France Innovation Fund: Rolling applications from July 2026. Best if you've already raised Seed or Series A funding and need co-investment or grant top-up.
  • Researcher mobility: Rolling. Best if you need specialist talent or want to embed researchers in your team.

Step 4: Draft the Joint Proposal

Work closely with your French partner. Key components:

  • Project rationale and impact in plain English and French.
  • Workplan broken into UK and France work packages (both councils want clarity on who does what where).
  • Budget breakdown by country and partner.
  • IP ownership and commercial exploitation plan (required by both councils).
  • Risk mitigation tied to cross-border logistics.

Proposal quality is competitive. Allocate 8–12 weeks to drafting, internal review, and external feedback.

Step 5: Submit via UKRI and Monitor

Your UK-based team submits through UKRI's portal. Your French partner submits to ANR simultaneously (same deadline, synchronised by bilateral agreement). Assessment happens in both countries. Expect notification within 6 months.

Intellectual Property

The agreement mandates co-ownership for jointly-developed IP, unless you negotiate otherwise upfront. Standard model: both parties own invention jointly; either party can licence independently to third parties (with royalty-sharing). This protects both sides and accelerates commercialisation.

Action: in your project contract, specify IP split (50/50 is standard) and define what counts as "joint" (usually anything developed during the project using joint resources).

Tax and Grant Treatment

In the UK, ANR funding is treated as non-taxable research income (similar to UKRI grants). However, you should notify HMRC and your accountant. French tax treatment of UK grants is still being clarified by the French revenue authority; consult a French tax advisor if you're receiving funds as a UK company with French operations.

Important: SEIS/EIS investors should note that participating in bilateral research grants does not disqualify your startup from EIS status, provided your company remains within EIS trade rules (i.e., not financial services, property, etc.).

Regulatory and Compliance Issues

If your research touches export-controlled technology (aerospace, defence-adjacent tech, dual-use materials), check UK Department for Science, Innovation and Technology (DSIT) export controls guidance and French DCNS equivalents. The bilateral agreement does not waive export licensing; you still need permissions for sensitive tech transfer.

Real-World Example: How a Cleantech Startup Taps the Deal

Imagine Helix Energy, a UK deep-tech startup developing advanced thermal batteries for industrial waste-heat recovery. They've raised £800k seed funding. Their technical co-founder did a PhD at Imperial on materials science.

Opportunity: a team at IRDEP in Paris has published on similar thermal-storage materials. Helix proposes a joint 3-year project: Helix does prototype engineering and commercial viability; IRDEP runs materials characterisation and optimisation.

Route:

  1. Helix contacts IRDEP via IMREDD (French materials research network) and proposes collaboration.
  2. IRDEP agrees and drafts a collaboration agreement. Cost to Helix: ~£3k in legal fees and 2–3 months elapsed time.
  3. Helix and IRDEP jointly apply to ANR-UKRI in October 2026. Budget: £400k total (split 60/40, Helix/IRDEP).
  4. If awarded (April 2027), Helix receives £240k non-dilutive funding over 3 years. IRDEP receives €160k.
  5. IP: jointly owned. Helix can commercialise; IRDEP can publish (with 3-month delay for Helix to file patents).
  6. Benefit: Helix accelerates R&D, de-risks technical risk, and gains credibility with Series A investors and corporate customers.

Timeline to first funding cheque: 8 months. Non-dilutive capital: £240k—equivalent to raising a small seed round without equity dilution.

Looking Ahead: What Comes Next

The UK-France deal is a template. Both governments have publicly signalled that similar arrangements with other European countries (Germany, Netherlands, Spain) are in negotiation. By 2027, UK startups may have access to a federated network of bilateral research-funding pathways—falling short of full Horizon Europe re-entry, but materially improving cross-border research access.

Key dates to watch:

  • July 2026: UK-France Innovation Fund applications open. First cohort of 15–20 startups expected by Q4 2026.
  • August 2026: UKRI and Bpifrance announce second tranche of joint-priority research themes (beyond the four named above).
  • November 2026: First ANR-UKRI joint research-grant round closes. 150–200 applications expected; 25–35 funded.
  • Q1 2027: First funded projects launch. Early data on impact, drop-out rates, and commercialisation emerges.
  • Q4 2027: Deal renewal discussions; likelihood of expanded scope and increased funding allocation.

For UK startup founders, the message is clear: if your company operates in deep tech, has clear research dependencies, or benefits from European partnerships, the window to tap this new infrastructure is open now. First-mover advantage is real—the inaugural funding rounds will be smaller and less competitive than they'll become in 18 months.

Conclusion: A Watershed Moment for UK-Europe Tech Collaboration

The UK-France science and technology deal marks the first material reopening of cross-border research collaboration pathways since Brexit. It won't restore Horizon Europe access or eliminate all friction, but it meaningfully reduces it for startups and research-intensive companies willing to build genuine partnerships with French institutions.

For founders in cleantech, biotech, AI, quantum, and advanced manufacturing, the practical impact is substantial: new sources of non-dilutive funding, faster de-risking of core R&D, and easier access to world-class research talent and infrastructure. The mechanics are complex but navigable—and the payoff (£150k–£500k in research funding per project, or £50k–£250k in Innovation Fund co-investment) justifies the upfront compliance and administrative work.

The broader signal: the UK is rebuilding its international science networks outside the formal EU framework. This deal is the first domino. Others will follow. For startup founders, this is an inflection point to re-engage with European research partnerships, secure in the knowledge that legal, financial, and IP frameworks are finally in place to make cross-border collaboration viable again.

The next 18 months are the time to move. Applications for the inaugural rounds open now. Partnership opportunities with French labs and investors are abundant. The infrastructure is here. The funding is available. The only variable left is founder action.